A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of GX-I7 in HPV-infected Female Volunteers
Phase of Trial: Phase I
Latest Information Update: 07 Jun 2018
At a glance
- Drugs GX I7 (Primary)
- Indications Human papillomavirus infections
- Focus Adverse reactions
- Sponsors Genexine
- 01 Jun 2018 Planned End Date changed from 30 Mar 2018 to 30 Jun 2018.
- 01 Jun 2018 Planned primary completion date changed from 15 Dec 2017 to 30 Jun 2018.
- 11 May 2017 New trial record